Nonetheless, based on the data analyzed here, we conclude that KRAS should be considered as a potent target for the CRISPR systems, for cancer therapeutics. Furthermore, we conclude that due to the collaterally dependent genes and their implications in the evolution of cancer, KRAS mutations should not be targeted alone, but together with related molecules in relevant pathways. Here, KRAS is linked to cancer.